| Autor: |
Prabhash K; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India. kprabhash1@gmail.com., Advani SH; Department of Medical Oncology, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India., Batra U; Department of Thoracic Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India., Biswas B; Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India., Chougule A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India., Ghosh M; Department of Clinical Genomics and Translational Research, Triesta Sciences, Bengaluru, Karnataka, India., Muddu VK; Department of Medical Oncology, Apollo Health City, Jubilee Hills, Hyderabad, Telangana, India., Sahoo TP; Department of Medical Oncology, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India., Vaid AK; Department of Medical and Hemato-oncology, Cancer Institute, Medanta - The Medicity, Gurugram, Haryana, India. |
| Abstrakt: |
Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Indian clinical and pathology settings has been challenging due to operational and logistical constraints. This consensus guideline brings together medical oncologists, molecular pathologists and pathologists from India to provide a quick and competent reference for biomarker testing in NSCLC. The guideline summarizes the importance of targetable mutations in NSCLC such as epidermal growth factor receptor (EGFR), rearrangements in anaplastic lymphoma kinase and receptor tyrosine kinase encoded by ROS-1 gene, overexpression of programmed cell death ligand-1 and resistant EGFR mutations. It reaffirms recommendations from international working groups, discusses vulnerable pre-analytical procedures and provides a balanced review on the pros and cons of different diagnostic tests (immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction-based testing and next-generation sequencing). The document also provides an algorithm to aid diagnostic decision-making and a checklist to assess the quality of testing laboratories that will help the medical oncologists make an informed choice. Overall, these recommendations are based on evidence and clinical experience and will aid policymakers, oncologists, health care practitioners and pathologists who strive to implement molecular strategies and make informed decisions for improved care in NSCLC in India.Funding: AstraZeneca Pharma India Limited. |
Full text from SpringerLink